Please explain how Novartis can know of any results from a double blinded phase III trial, that led to this partnership?
All they can really know is, that the trial was recommended to continue?
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS, page-336
-
- There are more pages in this discussion • 237 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.020(1.83%) |
Mkt cap ! $1.255B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $2.726M | 2.477M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 31152 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 25072 | 19 |
View Market Depth
| Last trade - 14.48pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |